Report Highlights
The global cardiac biomarkers market has grown to $4.9 billion in 2015 from $4.4 billion in 2014. The market is expected to grow at a five-year compound annual growth rate (CAGR) of 12.4% from 2015 to 2020, increasing to over $8.8 billion in 2020.
Report Includes
- An overview of the global market for cardiac biomarkers and related technologies.
- Analyses of global market trends, with data from 2014, 2015, and projections of CAGRs through 2020.
- Classification of cardiac biomarkers by cerebrovascular, congestive, coronary, hypertensive, and peripheral arterial disease.
- Background and clinical values of cardiac biomarkers, including B-type natriuretic peptide (BNP), N-terminal pro-B-type natriuretic peptide (NT-proBNP), C-reactive protein (CRP), choline, creatine kinase MB (CK-MB), D-dimer, glial fibrillary acidic protein (GFAP), heart fatty acid binding protein (H-FABP), ischemia-modified albumin (IMA), myeloperoxidase (MPO), myoglobin, soluble fragment CD40 ligand (sCD40L), and troponin I (cTnI)/troponin T (cTnT).
- Examination of the technology covering diagnostic methods, instrumentation, newly issued patents, and new patent applications.
- Clinical guidelines and government regulations.
- Profiles of major players in the industry.
Report Scope
Current and projected assay revenues during the forecast period (2015 through 2020) are presented. In addition, newly developed assays with regulatory approval and others expected to receive U.S. Food and Drug Administration approval within the forecast period are also projected. Figures for 2015 are estimated, except where actual results have been reported, because of the timing of the release of this report. For large market segments, such as cTn and natriuretic peptides, the analytical sensitivities and cutoff references for the diagnosis and prognosis values are discussed in detail. Moreover, the ongoing effort in developing a high-sensitivity troponin assay, as well as the attempt to pursue additional biomarkers for the diagnosis of congestive heart failure (CHF) and strokes are focused on in this study.
The report includes an analysis of leading and emerging competitors in the current global diagnostics market for CVDs. Profiles of manufacturers of leading products as well as biotechnology companies with products in development are discussed to define their specific product strategies. The competitive environment is examined, with a special focus on how instrumentation type (clinical chemistry analyzers compared with point-of-care devices) and their respective technologies are influencing the current standard of care. Detailed profiles of current market leaders are discussed, as well as companies with innovative products poised to enter the market during the forecast period.
Market figures are based on revenues at the manufacturers’ level and are projected at 2015-U.S.-dollar value. Inflation is not computed into the projection figures. Trends are assessed based on projected sales for existing products, new product introductions, expanded indications for existing products and projected changes in the prevalence and diagnosis of respective diseases. Included in this report are forecasts by product, product category and by company from 2014 through 2020. The study is arranged to offer an overview of the diagnostics market accompanied by product, company and region.
Excluded from this report are nonproteomic diagnoses (i.e., molecular diagnostics), imaging technology and pharmaceutical biomarkers. Sales figures are reported in U.S. dollars, and in each case, these reflect currency fluctuations within the performance of changes in sales. Sales figures do not account for variation in local currencies. All market share data presented are on a global basis, unless specifically noted.
Analyst Credentials
ANUJ PATHAK has written and researched the global medical device market, surgical instruments and biotechnology market. Skilled in information technology and computer management, he has an undergraduate business degree and an MBA degree.
Related Reports
Biomarkers: Technologies and Global Markets
The global market for biomarkers was valued at $63.7 billion in 2023. This market is expected to grow from $70.5 billion in 2024 to $130.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 13.1% from 2024 through 2029.
Central Nervous System (CNS) Biomarkers: Technologies and Global Markets
The global central nervous system (CNS) biomarkers market should reach $9.5 billion by 2027 from $5.7 billion in 2022 at a compound annual growth rate (CAGR) of 10.8% for the forecast period of 2022 to 2027.
Cardiovascular Devices: Global Markets to 2022
The global market for cardiovascular devices reached nearly $42.4 billion in 2017 and should reach $59.1 billion by 2022, at a compound annual growth rate (CAGR) of 6.9% for the period of 2017-2022.
Emerging Diagnostic Technologies in the Changing U.S. Market
The U.S. emerging diagnostic technologies market was valued at $880 million in 2011 and should reach $1.2 billion in 2012. Total market value is expected to reach $3.2 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 20.9%.
Track the Latest Global Tariff Developments
In today's fast-paced global economy, tariffs are no longer static—they are dynamic levers shaped by geopolitical realignments, supply chain vulnerabilities, inflationary pressures, and sustainability-driven trade reforms. As governments worldwide recalibrate their trade strategies, businesses are left to navigate a maze of shifting rules, rising costs, and regulatory uncertainty.
Our analysis empowers you with real-time updates and in-depth expert analysis on all facets of global tariff activity. From new trade agreements and sanctions to abrupt tariff hikes and retaliatory duties, we monitor developments across borders, sectors, and industries—so you don't have to.
Whether it's the ongoing U.S.–China trade dynamics, the evolving EU Carbon Border Adjustment Mechanism (CBAM), or the emerging policies in India, ASEAN, and Latin America, we provide full-spectrum coverage. We also track multilateral trade negotiations, World Trade Organization (WTO) rulings, and sector-specific duty structures—ensuring you are always ahead of global trade shifts.
With our analysis, you can stay informed, identify risks, and confidently respond to tariff changes—no matter where you operate.
Ready to see what tariff means for your business?
Consult with our experts or request your custom Tariff Impact Brife today
Stay Informed, Stay Competitive
In today's interconnected and unpredictable global economy, staying ahead of tariff shifts is not just important—it's essential. BCC Research provides decision-makers with trusted, research-driven insights that turn uncertainty into opportunity.
Our in-depth market analysis and trade intelligence help you decode how tariff changes impact your specific sector—manufacturing, healthcare, technology, agriculture, or energy. We break down complex data into actionable knowledge through comprehensive reports, expert commentaries, and sector-focused forecasts.
Our analysis includes:
- Thorough breakdowns of current and proposed tariff policies and how they affect regional and global trade flows.
- Sector-specific implications, helping you understand the strategic impact on sourcing, pricing, and competitiveness.
- Forward-looking insights to support risk management, planning, and response strategies for evolving trade conditions.
With BCC Research, you gain more than just information—you gain clarity and confidence to make well-informed decisions in a volatile trade environment.
Don't let tariffs catch you off guard—let our insights guide your strategy.
Recent Reports
Global Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market
The global market for irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) therapeutics is expected to grow from $33.3 billion in 2025 and is projected to reach $52.6 billion by the end of 2030, at a compound annual growth rate (CAGR) of 9.6% during the forecast period of 2025 to 2030.
Global DNA Forensics Market
The global market for DNA forensics is projected to grow from an estimated $3.3 billion in 2025 to $4.7 billion by the end of 2030, at a compound annual growth rate (CAGR) of 7.7% from 2025 to 2030.
Global Blood Platelet Market
The global market for blood platelets is expected to grow from $3.2 billion in 2025 and is projected to reach $4 billion by the end of 2030, at a compound annual growth rate (CAGR) of 4.6% during the forecast period of 2025 to 2030.
Digital Biomarkers: Global Markets
The global market for digital biomarkers is estimated to grow from $5 billion in 2025 to $18.8 billion by the end of 2030, at a compound annual growth rate (CAGR) of 30.4% from 2025 through 2030.
Whole Genome Sequencing: Global Markets
The global market for whole genome sequencing is expected to grow from $3 billion in 2025 and forecast to reach $6.1 billion by the end of 2030, at a compound annual growth rate (CAGR) of 15.1% from 2025 to 2030.
Report Highlights
The global market for in vitro diagnostic tests for cardiac biomarkers was estimated at $3.1 billion in 2012 and nearly $4 billion in 2013. This market is predicted to reach $7.2 billion by 2018, at a compound annual growth rate (CAGR) of 12.8% over the five-year period from 2013 to 2018.
Report Includes
- An overview of the global market for biomarkers for cardiovascular disease (CVD) and related technologies.
- Analyses of global market trends, with data from 2012, estimates for 2013, and projections of CAGRs for the period 2013 to 2018.
- Classification of CVD by cerebrovascular, congestive, coronary, hypertensive, and peripheral arterial disease.
- Background and clinical values of cardiac biomarkers, including B-type natriuretic peptide (BNP), N-terminal pro-B-type natriuretic peptide (NT-proBNP), C-reactive protein (CRP), choline, creatine kinase MB (CK-MB), D-dimer, glial fibrillary acidic protein (GFAP), heart fatty acid binding protein (H-FABP), ischemia-modified albumin (IMA), myeloperoxidase (MPO), myoglobin, soluble fragment CD40 ligand (sCD40L), and troponin I (cTnI)/troponin T (cTnT).
- Examination of the technology covering diagnostic methods, instrumentation, newly issued patents, and new patent applications.
- Clinical guidelines and government regulations.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More